Commentary

Article

State of the Science Summit - Melanoma: Chaired by Ankit Mangla, MD

State of the Science Summit - Melanoma: Chaired by Ankit Mangla, MD

State of the Science Summit - Melanoma: Chaired by Ankit Mangla, MD

Speakers

  • Luke Rothermel, MD | University Hospitals Seidman Cancer Center
  • Igor Puzanov, MD, MSCI, FACP | Roswell Park Comprehensive Cancer Center
  • Thach Giao Truong, MD | Cleveland Clinic
  • Iris Y. Sheng, MD | University Hospitals Seidman Cancer Center

Topics

  • Surgical Perspectives in Melanoma
  • Adjuvant and Neoadjuvant Therapy for Advanced Melanoma
  • Role of Immunotherapy: How Do You Select Frontline Therapy for Advanced Melanoma?
  • Clinical Scenarios: Neoadjuvant/Adjuvant Therapies in Melanoma
  • BRAF-Targeted Therapies in Advanced Melanoma
  • Clinical Scenarios: Targeted Therapies in Melanoma

Interested in virtually attending an IPC event? Click here to register for an upcoming webinar.

Some of the episodes from our podcast, OncLive On Air, are focused on the interviews with faculty conducted at the State of the Science SummitsClick here to listen to our latest episodes!

Related Videos
Ahmad Tarhini, MD, PhD
Ahmad Tarhini, MD, PhD
Georgina V. Long, MBBS, PhD, FRACP
Nikhil Khushalani, MD, vice chair, Department of Cutaneous Oncology, Moffitt Cancer Center
Axel Hauschild, MD, PhD, head, Skin Cancer Trial Center, University Hospital Schleswig-Holstein
Ahmad Tarhini, MD, PhD
Nivolumab plus relatlimab vs nivolumab in previously untreated metastatic or unresectable melanoma (RELATIVITY-047): overall survival and melanoma-specific survival outcomes at 3 years
Long-term follow up for adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma: Final results of the COMBI-AD study
 Phase 3 study (PIVOTAL) of neoadjuvant intralesional daromun vs. immediate surgery in fully resectable melanoma with regional skin and/or nodal metastases
Zeynep Eroglu, MD